Core Insights - The company reported a significant increase in revenue and profit for the first three quarters of 2025, with total revenue reaching 7.897 billion and net profit attributable to shareholders at 732 million, reflecting year-on-year growth of 30.10% and 32.36% respectively [1] - The consumer segment, particularly the ToC brand "Cotton Era," has been a key driver of growth, achieving revenue of 4.01 billion with a year-on-year increase of 19.1% [1] - The medical segment has also shown strong performance, with revenue of 3.83 billion, marking a substantial year-on-year growth of 44.4% [2] Consumer Segment Performance - The "Cotton Era" brand has focused on core categories and strategic products, leading to differentiated growth advantages [1] - Notable products include the "Princess Nais" sanitary napkins, which generated 760 million in sales, a remarkable increase of 63.9% [1] - Other core categories such as wet and dry cotton soft towels and adult apparel also maintained steady growth, with revenues of 1.17 billion and 750 million, reflecting year-on-year growth of 15.7% and 17.3% respectively [1] Channel Development - The company has established a synergistic online and offline sales strategy, with e-commerce channels generating 2.46 billion in revenue, a year-on-year increase of 23.5% [2] - Interest e-commerce platforms, particularly Douyin, have seen nearly 80% growth, becoming a new growth engine for online sales [2] - The supermarket channel has expanded rapidly, achieving 360 million in revenue, a significant increase of 53.4% [2] Medical Segment Performance - The medical segment has optimized its product structure, with core categories such as surgical consumables and high-end dressings showing rapid growth [3] - Surgical consumables achieved revenue of 1.15 billion, a staggering increase of 185.3% [3] - High-end dressings and health personal care products also contributed positively, with revenues of 720 million and a year-on-year growth of 26.2% and 24.6% respectively [3] Future Strategy - The company aims to continue its strategy of "product leadership, excellent operations, and global vision," focusing on core areas and expanding both domestic and international markets [3] - Ongoing product innovation, channel penetration, and brand upgrades are expected to enhance the company's core competitiveness in the health sector [3]

Investment Rating - The report maintains an "Accumulate" rating for the company [1]. Core Insights - The company achieved a high-quality growth in Q3 2025, with revenue reaching 7.9 billion yuan, a year-on-year increase of 30.1%, and a net profit attributable to shareholders of 730 million yuan, up 32.4% year-on-year [5][9]. - The medical and consumer sectors both contributed significantly to the revenue growth, with the medical segment growing by 44.4% and the consumer segment by 19.1% in the first three quarters of 2025 [6][7]. Summary by Sections Financial Performance - For Q3 2025, the company reported revenues of 2.6 billion yuan, with a year-on-year growth of 27.7%. The net profit for the same quarter was 240 million yuan, reflecting a 42.1% increase year-on-year [5][6]. - The company's gross margin improved to 48.3%, up 0.2 percentage points year-on-year, while the expense ratio decreased by 1.1 percentage points to 35.7% [8]. Revenue Breakdown - The medical business generated 3.83 billion yuan in revenue in the first three quarters, accounting for 48.5% of total revenue, with a notable growth in key categories such as surgical consumables and high-end dressings [6]. - The consumer business achieved 4.01 billion yuan in revenue, representing 50.8% of total revenue, with significant growth in products like sanitary napkins and adult products [7]. Profitability and Valuation - The report forecasts net profits for 2025, 2026, and 2027 to be 1.019 billion yuan, 1.214 billion yuan, and 1.431 billion yuan respectively, with corresponding EPS of 1.75 yuan, 2.08 yuan, and 2.46 yuan [9][11]. - The company is expected to trade at a P/E ratio of 22, 18, and 16 for the years 2025, 2026, and 2027 respectively [9][11].

Core Insights - The company reported significant growth in revenue and profit for the first three quarters of 2025, with total revenue reaching 7.897 billion yuan, a year-on-year increase of 30.10%, and net profit attributable to shareholders at 732 million yuan, up 32.36% [1] - The company's dual business segments, medical and consumer, are performing well, enhancing brand influence and product competitiveness, laying a solid foundation for sustainable growth and value enhancement [1] Consumer Segment Performance - The consumer segment achieved a total revenue of 4.01 billion yuan in the first three quarters of 2025, reflecting a year-on-year growth of 19.1%, with steady improvements in gross and operating profit margins [2] - Key products such as the Princess Nais sanitary napkin saw remarkable sales of 760 million yuan, a substantial increase of 63.9%, driving growth in the segment [2] - The company has established a balanced online and offline sales strategy, with e-commerce revenue reaching 2.46 billion yuan, up 23.5%, and supermarket channel revenue growing by 53.4% to 360 million yuan [2] Brand Strategy - The company is focusing on a "brand upward" strategy, emphasizing "safety, happiness, and sustainability" to enhance user recognition and experience [3] - Initiatives include celebrity endorsements and thematic events to deepen emotional connections with consumers, alongside the opening of a flagship store in Wuhan to showcase the brand's lifestyle [3] Medical Segment Performance - The medical segment reported a revenue of 3.83 billion yuan in the first three quarters of 2025, a significant increase of 44.4%, outpacing the overall company growth [4] - The product mix has been optimized, with high-value and high-margin products gaining a larger share, including surgical consumables and high-end dressings [4] - The international market contribution has increased significantly, with overseas sales reaching 2.18 billion yuan, a year-on-year increase of 81.7%, now accounting for 57% of the medical segment's revenue [4] Professional Brand Image - The company is enhancing its professional brand image through participation in major industry expos and showcasing innovative solutions like the "green operating room" [5] - The production of "lead-free" medical radiation protection clothing has garnered industry attention, highlighting the company's technological leadership [5] Synergistic Growth - The medical and consumer segments are creating a synergistic "dual-engine" growth model, where the medical segment's technical expertise supports the consumer segment's brand influence, and vice versa [6] - The company aims to continue its strategy of product leadership, operational excellence, and global vision, focusing on core areas and expanding both domestic and international markets [6]

Investment Rating - The report maintains a "Buy" rating for the company [2][6][7] Core Insights - The company reported a strong performance in H1 2025, with total revenue reaching 5.3 billion yuan, a year-on-year increase of 31.3%, and a net profit attributable to shareholders of 492 million yuan, up 28.1% [6][12] - The medical business showed significant growth, with revenue in the medical segment increasing by 46.4% year-on-year, contributing 47% to total revenue [7][12] - The consumer goods segment also performed well, with a revenue increase of 20.3% year-on-year, accounting for 52% of total revenue [7][12] Financial Data and Profit Forecast - Total revenue projections for 2025 are estimated at 10.779 billion yuan, with a year-on-year growth rate of 20.1% [6][18] - The net profit attributable to shareholders is forecasted to reach 1.026 billion yuan in 2025, reflecting a significant increase of 47.5% year-on-year [6][18] - The earnings per share (EPS) for 2025 is projected to be 1.76 yuan, with a price-to-earnings (PE) ratio of 24 [6][18] Business Performance - The medical business's revenue for H1 2025 was 2.52 billion yuan, with a gross margin of 37.4% [7][12] - The consumer goods segment's revenue for H1 2025 was 2.75 billion yuan, with a gross margin of 58.6% [7][12] - The company has maintained a strong cash position, with cash and cash equivalents amounting to approximately 1.5 billion yuan [7][12]

Investment Rating - The investment rating for the company is "Buy" (maintained) [3][6]. Core Insights - The company reported a strong performance in H1 2025, achieving revenue of 5.3 billion yuan, a year-on-year increase of 31.3%, and a net profit attributable to shareholders of 490 million yuan, up 28.1% year-on-year [5][6]. - The medical segment showed robust growth, with revenue of 2.52 billion yuan in H1, a year-on-year increase of 46.4%. Excluding the newly acquired GRI, the medical segment's revenue was 1.95 billion yuan, up 13.2% year-on-year [5][6]. - The consumer goods segment also performed well, with revenue of 2.75 billion yuan in H1, a year-on-year increase of 20.3%. The core product categories, such as sanitary napkins, saw significant growth, with revenue increasing by 67.6% [5][6]. Financial Performance Summary - H1 2025 revenue breakdown: - Medical segment: 2.52 billion yuan, up 46.4% year-on-year - Consumer goods segment: 2.75 billion yuan, up 20.3% year-on-year - H1 2025 net profit: 490 million yuan, up 28.1% year-on-year - H1 2025 gross margin: 48.3%, down 0.4 percentage points year-on-year [5][6]. Earnings Forecast and Investment Recommendations - The company plans to distribute a mid-term dividend of 260 million yuan, with a payout ratio of 53% [5][6]. - Forecasted net profits for 2025-2027 are 1 billion yuan, 1.21 billion yuan, and 1.45 billion yuan, with growth rates of 43.8%, 21.0%, and 19.7% respectively [5][6].

Group 1: Company Overview - Steady Medical Group, founded in 1991, has evolved into a health enterprise focusing on medical and consumer sectors, listed on the Shenzhen Stock Exchange in 2020 [13] - The company aims to "protect health, care for life, and protect the environment" with its main brands being "Winner Medical" and "Purcotton" [13] Group 2: Annual Performance Review - In 2024, the company achieved a total revenue of 89.8 billion CNY, a 9.7% increase from 2023's 81.9 billion CNY [18] - Excluding infection protection product revenue, the adjusted revenue was 86.2 billion CNY, reflecting an 18.6% year-on-year growth [18] - The revenue structure for 2024 was 43% from medical consumables and 56% from consumer products [18] Group 3: Profitability - The net profit attributable to shareholders reached 7.0 billion CNY, a 19.8% increase compared to 2023 [21] - The net profit margin improved to 7.7%, up 0.7 percentage points from the previous year [21] - The gross profit margin for 2024 was 47.3%, indicating a stable profitability trend [20] Group 4: Asset Quality and R&D Investment - Total assets at the end of 2024 were 184 billion CNY, a 7.5% increase from the previous year [26] - The asset-liability ratio stood at 35.4%, maintaining a low level [26] - The company emphasized R&D, with a steady increase in the number of patents and medical product registrations [26] Group 5: Shareholder Returns - The proposed cash dividend for 2024 is 3.8 billion CNY, representing 54% of the net profit [30] - Cumulative cash dividends since listing amount to 26.1 billion CNY, accounting for 93% of the net proceeds from the IPO [30] Group 6: Medical Consumables Business - The medical segment generated 39.1 billion CNY in revenue for 2024, showing resilience despite a high base from infection protection products [34] - Excluding infection protection, the medical consumables revenue was 35.5 billion CNY, a 20.4% increase year-on-year [34] - Core categories such as high-end dressings and surgical consumables saw revenue growth exceeding 30% [34] Group 7: Consumer Products Business - The consumer segment, led by Purcotton, achieved 49.9 billion CNY in revenue, a 17.1% increase from 2023 [43] - Online sales contributed 62% of the revenue, while offline stores accounted for 30% [46] - The company added 92 new offline stores in 2024, bringing the total to 487 [46] Group 8: Q1 2025 Performance Overview - In Q1 2025, total revenue reached 26.1 billion CNY, a 36.5% increase year-on-year [53] - The medical business revenue for Q1 2025 was 12.5 billion CNY, up 46.3% [54] - The consumer business generated 13.4 billion CNY, reflecting a 28.8% growth [54]